Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

The objective of this non-interventional multicenter study is to provide prospective, observational data on patients initiating treatment with palbociclib combination to contribute to the knowledge of HR+ HER2-metastatic/locally advanced Breast Cancer (BC) disease management, its treatment pattern, clinical outcomes and quality of life (QoL) in the routine clinical practice in Africa and Middle East countries .

Inclusion Criteria: 1. ≥18 years or older with diagnosis of adenocarcinoma of the breast with evidence of metastatic /locally advanced disease not amenable to treatment with curative intent. 2. Documented HR+ (ER+ and/or PR+) tumor based on local standards 3. Documented HER2- tumor based on local standards 4. Will initiate treatment with palbociclib plus letrozole/aromatase inhibitor or palbociclib plus fulvestrant in line with the licensed indication(s), as first or second line therapy for metastatic/locally advanced BC at enrollment 5. Patients who in the opinion of the investigator are willing and able to comply with regular clinic visits 6. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: 1. Patients participating in any interventional clinical trial 2. Patients on active treatment for malignancies other than metastatic/locally advanced BC at the time of enrollment 3. Patients who are unable to understand the nature of the study and are unwilling to sign an informed consent